2020
Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA , et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.
View Abstract
Topics: Cancer
Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA , et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.
View Abstract
Topics: Cancer
Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA , et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.
View Abstract
Topics: Cancer
Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA . A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. 2020. J Cancer Edu 35(1):178–186.
View Abstract
Topics: Cancer
Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA , et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.
View Abstract
Topics: Cancer , Epidemiology
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M , et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.
View Abstract